Investors

Performance

Revenue ($m)

$2,207m

Operating profit/(loss) ($m)

$493m

Core¹ operating profit ($m)

$508m

EBITDA² ($m)

$592m

Profit/(loss) to shareholders ($m)

$486m

Basic earnings/(loss) per share (cents)

201c

Core basic earnings per share³ (cents)

150c

Dividend per share (cents)

44c

Notes

Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 in the Notes to financial statements. A reconciliation from core to reported operating profit is included within the Consolidated income statement in the Financial statements
EBITDA is earnings before interest, tax, depreciation, amortisation and impairment charges. EBITDA is a non-IFRS measure, see page 30 for a reconciliation to reported IFRS results
Core basic earnings per share is reconciled to basic earnings per share in Note 15 in the Notes to the financial statements

Five reasons to invest in Hikma

We have a long track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success.

1Unique and diversified business model

Our business is uniquely positioned, with three main distinct business segments with strong foundations in the US, MENA and Europe. Our large and broad product portfolio is sold in both the retail and hospital markets.

2Strong market position

We are the third largest generic injectable manufacturer and a top ten generic company overall in the US with an increasing market share. In MENA, we are one of the largest pharmaceutical companies and a ‘partner of choice’.

3Commitment to quality

We have built our reputation on manufacturing high-quality medicines. Quality is embedded in our people, our relationships and our thinking. Our excellent track record of regulatory compliance has made us a trusted partner for our customers and patients.

4Large and growing pipeline

We have a large pipeline, with an increasing proportion of differentiated and complex products. We complement our internal development with partnerships and M&A.

5Cash generation

We have consistently generated strong cash flow. Our disciplined approach to cash management and acquisitions ensures we maintain a strong balance sheet and gives us the financial flexibility to support future growth.